Furthermore, targeted interventions against the NFATc3/LRRC55/BK channel axis may represent novel therapeutic approaches for MN and other related renal diseases, enhancing the quality of life for patients with renal diseases and slowing the progression of renal failure. This evidence concerns the gene NFATC3 and kidney disorder.